



A novel dual-action drug targeting cancer and respiratory syndromes

A novel compound inhibiting translation and inducing p53 independently of DNA damage, with potential for treating both cancer and acute respiratory syndromes.

IP Status: Issued US Patent; **Issued Patent No.** 11,439,656

Applications

- Cancer treatment
- Acute respiratory syndrome treatment

Key Benefits & Differentiators

- Exerts two anti-cancer effects simultaneously: 4Ei-10 molecule both inhibits proliferation (through blocking cap-dependent protein translation) and induces cell-cycle arrest and apoptosis (through upregulation of p53).
- Minimizes side-effects and risk of future cancers developing: Unlike most chemotherapy compounds, 4Ei-10 works without causing DNA-damage.
- Effective against a wide variety of cancers: As p53 has been shown to combat many cancers, 4Ei-10 has exhibited effectiveness against a variety of cancer cell lines in vitro.

Technology Overview

Researchers at the University of Minnesota have developed a small molecule (4Ei-10) that shows promise not only in the treatment of cancer but also in addressing acute respiratory syndromes. This compound achieves its anti-cancer effects through two distinct mechanisms: first, by inhibiting the translation of new proteins, thereby blocking cell proliferation, and second, by activating the potent anti-cancer protein, p53, which induces cell cycle arrest and apoptosis. Importantly, unlike traditional chemotherapeutic drugs, 4Ei-10 achieves p53 upregulation without causing DNA damage, potentially mitigating both the side effects associated with current treatments and the risk of secondary cancers. This dual mode of action positions 4Ei-10 as a versatile therapeutic agent that could offer a "double-edged sword" against aggressive cancers while also holding promise for the treatment of acute respiratory syndromes.

Phase of Development

In vitro assessment. 4Ei-10 has been tested on a variety of cancer cells including neuroblastoma, pediatric glioma, breast cancer and prostate cancer cells showing it inhibits proliferation and increases apoptosis and cell cycle arrest.

Researchers

Da-Qing Yang, PhD
Assistant Professor, The Hormel Institute

Technology ID

20180103

Category

Life Sciences/Human Health
Life Sciences/Pharmaceuticals
Agriculture &
Veterinary/Veterinary Medicine

View online page



[External Link](http://www.cancer.umn.edu) (www.cancer.umn.edu)

Carston R. Wagner, PhD

Professor and Endowed Chair, Department of Medicinal Chemistry

[External Link](http://www.pharmacy.umn.edu) (www.pharmacy.umn.edu)

Publications

[*Induction of the p53 Tumor Suppressor in Cancer Cells through Inhibition of Cap-Dependent Translation*](#)

Molecular and Cellular Biology, <https://mcb.asm.org/content/38/10/e00367-17>

Ready for Licensing

This technology is now available for license! The University is excited to partner with industry to see this innovation reach its potential. Please contact us to share your business' needs and your licensing interests in this technology. The license is for the sale, manufacture or use of products claimed by the patents.